142 related articles for article (PubMed ID: 720789)
1. Audit confirms conclusions of UGDP study on oral diabetes drugs.
FDA Drug Bull; 1978 Dec-1979 Jan; 8(6):34-6. PubMed ID: 720789
[No Abstract] [Full Text] [Related]
2. [Oral therapy in diabetes].
Kirkeby K
Tidsskr Nor Laegeforen; 1973 Aug; 93(23):1620-1. PubMed ID: 4588817
[No Abstract] [Full Text] [Related]
3. [The venture of University Group Diabetes Program (UGDP). Some personal reflexions. Tolbutamide and phenformin under accusation].
Pirart J
Nouv Presse Med; 1972 Jan; 1(5):325-8. PubMed ID: 5010448
[No Abstract] [Full Text] [Related]
4. [Should the prescription of oral antidiabetic drugs be more limited? Results from controlled clinical trials].
Folling I
Tidsskr Nor Laegeforen; 1973 Aug; 93(23):1604-6. PubMed ID: 4769481
[No Abstract] [Full Text] [Related]
5. Editorial: Oral hypoglycemic drugs.
Scoville AB
J Tenn Med Assoc; 1975 Apr; 68(4):319-20. PubMed ID: 1117723
[No Abstract] [Full Text] [Related]
6. The tolbutamide controversy.
Compr Ther; 1975 May; 1(1):19-20. PubMed ID: 1222531
[No Abstract] [Full Text] [Related]
7. [Heart death and oral antidiabetics; the last judgement].
Touber JL
Ned Tijdschr Geneeskd; 1975 Sep; 119(39):1506-8. PubMed ID: 1101083
[No Abstract] [Full Text] [Related]
8. The oral hypoglycemic controversy. Stay as sweet as you are.
Gregory DR
Leg Aspects Med Pract; 1979 Mar; 7(3):16-9. PubMed ID: 106193
[No Abstract] [Full Text] [Related]
9. Comments on the UGDP study.
Schöffling K
Horm Metab Res; 1974; Suppl 4():188-91. PubMed ID: 4608018
[No Abstract] [Full Text] [Related]
10. Antidiabetic agents and vascular events.
Keen H
J Clin Pathol Suppl (R Coll Pathol); 1975; 9():99-105. PubMed ID: 783218
[No Abstract] [Full Text] [Related]
11. The oral antidiabetic agents.
Bierman EL
Am Fam Physician; 1976 Jan; 13(1):98-104. PubMed ID: 1251792
[TBL] [Abstract][Full Text] [Related]
12. Oral hypoglycaemic agents.
Med J Aust; 1973 Mar; 1(12):570-1. PubMed ID: 4700542
[No Abstract] [Full Text] [Related]
13. Oral hypoglycaemic agents--dangers and contraindications.
Ennis G
Med J Aust; 1976 Oct; 2(16):605, 608-9. PubMed ID: 1004309
[No Abstract] [Full Text] [Related]
14. Clinical pharmacology of oral antidiabetic agents (second of two parts).
Shen SW; Bressler R
N Engl J Med; 1977 Apr; 296(14):787-93. PubMed ID: 320484
[No Abstract] [Full Text] [Related]
15. [University Group Diabetes Program. The UGDP investigation remains clinically unacceptable].
Aarseth S
Tidsskr Nor Laegeforen; 1976 Aug; 96(22):1148. PubMed ID: 951693
[No Abstract] [Full Text] [Related]
16. The influence of diagnostic criteria on the mortality findings in the University Group Diabetic Programme study of diabetic therapy.
Gray RH
Med J Aust; 1973 Mar; 1(12):594-6. PubMed ID: 4573383
[No Abstract] [Full Text] [Related]
17. An historical view of the medical-social aspects of the UGDP.
Knowles HC
Trans Am Clin Climatol Assoc; 1977; 88():150-6. PubMed ID: 898533
[No Abstract] [Full Text] [Related]
18. Letter: Oral hypoglycaemics in diabetes mellitus.
Keen H; Jarrett RJ; Fuller JH
Lancet; 1975 Nov; 2(7940):865. PubMed ID: 53342
[No Abstract] [Full Text] [Related]
19. Editorial: Let's stop the Donnybrook. A perspective on the UGDP-Biometric Society Study.
Moser RH
JAMA; 1975 Mar; 231(12):1274-6. PubMed ID: 1172958
[No Abstract] [Full Text] [Related]
20. Oral diabetic drugs again held hazardous.
J Tenn Med Assoc; 1975 Apr; 68(4):343. PubMed ID: 1117724
[No Abstract] [Full Text] [Related]
[Next] [New Search]